Compare TSAT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSAT | ARVN |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 600.2M |
| IPO Year | 2021 | 2018 |
| Metric | TSAT | ARVN |
|---|---|---|
| Price | $49.46 | $7.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 19 |
| Target Price | ★ $37.00 | $15.05 |
| AVG Volume (30 Days) | 108.8K | ★ 736.1K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.01 | $6.97 |
| 52 Week High | $61.54 | $14.22 |
| Indicator | TSAT | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 32.15 |
| Support Level | $48.11 | N/A |
| Resistance Level | $52.11 | $9.69 |
| Average True Range (ATR) | 2.82 | 0.35 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 57.31 | 13.33 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.